Bendamustine
| Clinical data | |
|---|---|
| Trade names | Treanda, others |
| Other names | SDX-105 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608034 |
| License data | |
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | NA (intravenous only) |
| Protein binding | 94–96% |
| Metabolism | Hydrolyzed to inactive metabolites. Two minor metabolites (M3 and M4) formed by CYP1A2 |
| Elimination half-life | 40 min (bendamustine), 3 h (M3), 30 min (M4) |
| Excretion | ~50% urinary, ~25% fecal [3] |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.205.789 |
| Chemical and physical data | |
| Formula | C16H21Cl2N3O2 |
| Molar mass | 358.26 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Bendamustine, sold under the brand name Treanda among others, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma.[4][5] It is given by injection into a vein.[4]
Common side effects include low blood cell counts, fever, nausea, diarrhea, loss of appetite, cough, and rash.[4] Other severe side effects include allergic reactions and increased risk of infection.[4] Use in pregnancy is known to harm the baby.[4] Bendamustine is in the alkylating agents family of medication.[4] It works by interfering with the function of DNA and RNA.[4]
Bendamustine was approved for medical use in the United States in 2008.[4] It is on the World Health Organization's List of Essential Medicines.[6][7] It was originally made from nitrogen mustard.[4]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
- ^ "Bendamustine EPSL (Eugia Pharma (Australia) Pty Ltd)". Therapeutic Goods Administration (TGA). 13 March 2025. Retrieved 24 March 2025.
- ^ Dubbelman AC, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel E, et al. (March 2013). "Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy". Drugs in R&D. 13 (1): 17–28. doi:10.1007/s40268-012-0001-5. PMC 3627029. PMID 23322528.
- ^ a b c d e f g h i "Bendamustine Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
- ^ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 579. ISBN 9780857111562.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.